Journal Publications

• [1]Li Q., Fang H., Wang X., Hu G., Wang Q., Xu W. Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Bioorg Med Chem Lett, 2012, 22(2): 850-853.
• [2]Lv M., Chen Z., Hu G., Li Q. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov Today, 2015, 20(3): 332-346.
• [3]Yu Z., Ye S., Hu G., Lv M., Tu Z., Zhou K., Li Q. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Med. Chem., 2015, 7(3): 269-289.
• [4]Hu L., Wang Z., Yi R., Yi H., Xiao S., Chen Z., Hu G., Li Q. Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases. Curr Med Chem, 2017, 24(29): 3203-3215.
• [5]Ai J., Lv M., Li X., Chen Z., Hu G., Li Q. Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives. Medicinal Chemistry Research, 2018, 27(1): 161-170.
• [6]Xiao S., Li Q., Hu L., Yu Z., Yang J., Chang Q., Chen Z., Hu G. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go? Mini Rev Med Chem, 2019, 19(18): 1544-1557.
• [7]Yu Z., Chen Z., Su Q., Ye S., Yuan H., Kuai M., Lv M., Tu Z., Yang X., Liu R., Hu G., Li Q. Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives. Bioorg Med Chem, 2019, 27(6): 944-954.
• [8]Zheng B., Peng Y., Wu W., Ma J., Zhang Y., Guo Y., Sun S., Chen Z., Li Q., Hu G. Synthesis and structure-activity relationships of pyrazolo-[3,4-b]pyridine derivatives as adenosine 5'-monophosphate-activated protein kinase activators. Arch Pharm (Weinheim), 2019, 352(8): e1900066.
• [9]Chang Q., Long J., Hu L., Chen Z., Li Q., Hu G. Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents. Bioorg Med Chem, 2020, 28(9): 115404.
• [10]Hu L., Li L., Chang Q., Fu S., Qin J., Chen Z., Li X., Liu Q., Hu G., Li Q. Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. J Med Chem, 2020, 63(19): 11215-11234.
• [11]Hu L., Zhao R., Liu Q., Li Q. New Insights Into Heat Shock Protein 90 in the Pathogenesis of Pulmonary Arterial Hypertension. Front. Physiol., 2020, 11: 1081.
• [12]Huang P., Le X., Huang F., Yang J., Yang H., Ma J., Hu G., Li Q., Chen Z. Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. J Med Chem, 2020, 63(9): 4685-4700.
• [13]Liu R., Yu Z., Chen Z., Liu D., Huang F., Li Q., Hu G., Yi X., Li X., Zhou H., Liu Z. A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at G0/G1 phase and induces mitochondrial apoptosis in non-small cell lung cancer cells. PeerJ, 2020, 8: e9981.
• [14]Zhou Z., Long J., Wang Y., Li Y., Zhang X., Tang L., Chang Q., Chen Z., Hu G., Hu S., Li Q., Peng C., Chen X. Targeted degradation of CD147 proteins in melanoma. Bioorg Chem, 2020, 105: 104453.
• [15]Cao Y., Le X., Shi X., Hao C., Ma B., Chen Z., Hu G., Cao D., Li Q. Multistep virtual screening based identification of homeodomain-interacting protein kinase 2 inhibitors: An opportunity for treating Chronic Kidney Disease. Chemometrics and Intelligent Laboratory Systems, 2021, 219: 104440.
• [16]Xiao Z., Peng Y., Zheng B., Chang Q., Guo Y., Chen Z., Li Q., Hu G. Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-containing pyrazolo[3,4-b]pyridinones as a new series of AMPKa1beta1gamma1 activators. Arch Pharm (Weinheim), 2021, 354(7): e2000458.
• [17]Guo Y., Jiang X., Chang Q., Xiao Z., Chen Z., Jiang D., Hu G., Li Q. Novel pyrazolo[3,4-b]pyridine derivatives: Synthesis, structure-activity relationship studies, and regulation of the AMPK/70S6K pathway. Arch Pharm (Weinheim), 2022, 355(7): e2100465.
• [18]Hu L., Wang G., Zhao C., Peng Z., Tao L., Chen Z., Hu G., Li Q. Identification of selective homeodomain interacting protein kinase 2 inhibitors, a potential treatment for renal fibrosis. Bioorg Chem, 2022, 126: 105866.
• [19]Hu L., Zhao C., Chen Z., Hu G., Li X., Li Q. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition. Drug Discov Today, 2022, 27(5): 1457-1463.
• [20]Hao C., Cao M., Ouyang H., Chen Z., Hu G., Li Q. Recent advances in the development of HIPK2 inhibitors as anti-renal fibrosis agents. Future Med. Chem., 2023, 15(5): 453-465.